Silverback Therapeutics Aktie News

EURneffy 1 mg will be the first and only needle-free adrenaline available to younger children in the European Union ARS Pharma's partner, ALK-Abelló A/S, who owns the rights to market  EURneffy  in the EU, will distribute following expected authorization by the European Commission SAN DIEGO, Feb. 02, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company ...

California joins 23 other states eligible to receive free neffy ® (epinephrine nasal spray) at schools SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, announced today that California, t...

neffy is the first epinephrine product approved for use out of a hospital setting in China for adults and children ( > 30 kg) living with severe allergic reactions Pediatrix Therapeutics, which has a license from ARS Pharma to market  neffy  in China under the trade name 优敏速 ® , expects availability in the spring of 2026 SAN DIEGO, Dec. 29, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Na...

SAN DIEGO, Nov. 26, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced its participation at the Piper Sandler 37th Annual Healthcare Conference, December 2-4, 2025, in New York.

ARS Pharmaceuticals, Inc. ( SPRY ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Justin Chakma - Chief Business Officer Richard Lowenthal - Co-Founder, President, CEO & Director Eric Karas - Chief Commercial Officer Kathleen Scott - Chief Financial Officer Conference Call Participants Lachlan Hanbury-Brown - William Blair & Company L.L.C., Research Division Joshua Sch...

ARS Pharmaceuticals, Inc. delivered strong Q3 Neffy sales, doubling sequentially, but remains unprofitable with high SG&A expenses and no 2026 guidance. SPRY faces competitive threats from generics and upcoming alternatives, but patent litigation could delay generic Neffy entry until 2039. Neffy's needle-free, lower-cost profile is driving adoption, with growing prescriber base and internationa...

$32.5 million in revenue, including $31.3 million in  neffy U.S. net product revenue in third quarter of 2025

Offers no-hassle, free  virtual visit with healthcare provider for patients to receive neffy for $0 co-pay if eligible with commercial insurance Program is available to eligible patients who may already have an auto-injector, but are looking for a smaller, easier to administer option SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopha...